Unveiling the Potential of DT-168: Design Therapeutics to Showcase Promising Preclinical Data for Fuchs Endothelial Corneal Dystrophy Treatment at ARVO 2023
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a…